Correlation Between Virax Biolabs and DiaMedica Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Virax Biolabs and DiaMedica Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Virax Biolabs and DiaMedica Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Virax Biolabs Group and DiaMedica Therapeutics, you can compare the effects of market volatilities on Virax Biolabs and DiaMedica Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Virax Biolabs with a short position of DiaMedica Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Virax Biolabs and DiaMedica Therapeutics.

Diversification Opportunities for Virax Biolabs and DiaMedica Therapeutics

0.12
  Correlation Coefficient

Average diversification

The 3 months correlation between Virax and DiaMedica is 0.12. Overlapping area represents the amount of risk that can be diversified away by holding Virax Biolabs Group and DiaMedica Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on DiaMedica Therapeutics and Virax Biolabs is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Virax Biolabs Group are associated (or correlated) with DiaMedica Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of DiaMedica Therapeutics has no effect on the direction of Virax Biolabs i.e., Virax Biolabs and DiaMedica Therapeutics go up and down completely randomly.

Pair Corralation between Virax Biolabs and DiaMedica Therapeutics

Given the investment horizon of 90 days Virax Biolabs Group is expected to under-perform the DiaMedica Therapeutics. In addition to that, Virax Biolabs is 1.8 times more volatile than DiaMedica Therapeutics. It trades about -0.09 of its total potential returns per unit of risk. DiaMedica Therapeutics is currently generating about -0.09 per unit of volatility. If you would invest  534.00  in DiaMedica Therapeutics on December 29, 2024 and sell it today you would lose (120.00) from holding DiaMedica Therapeutics or give up 22.47% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Virax Biolabs Group  vs.  DiaMedica Therapeutics

 Performance 
       Timeline  
Virax Biolabs Group 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Virax Biolabs Group has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
DiaMedica Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days DiaMedica Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in April 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Virax Biolabs and DiaMedica Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Virax Biolabs and DiaMedica Therapeutics

The main advantage of trading using opposite Virax Biolabs and DiaMedica Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Virax Biolabs position performs unexpectedly, DiaMedica Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will offset losses from the drop in DiaMedica Therapeutics' long position.
The idea behind Virax Biolabs Group and DiaMedica Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Complementary Tools

Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Stocks Directory
Find actively traded stocks across global markets
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Equity Valuation
Check real value of public entities based on technical and fundamental data
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk